Datasheet for ABIN2745581

anti-VEGFR2/CD309 antibody

1 Image

Go to Product page

Overview

Quantity:	100 µg
Target:	VEGFR2/CD309 (VEGFR2)
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This VEGFR2/CD309 antibody is un-conjugated
Application:	Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Flow Cytometry (FACS)

Product Details

Immunogen:	Recombinant human soluble extracellular VEGFR-2.
Clone:	EIC
Isotype:	IgG1
Specificity:	The antibody will detect native human VEGFR-2/KDR in ELISA experiments and on the surface of different human cell types.
Cross-Reactivity:	Human
Purification:	Protein G purified.

Target Details

Target:	VEGFR2/CD309 (VEGFR2)
Alternative Name:	VEGFR-2/KDR (VEGFR2 Products)

Target Details

Background:	Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels, modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.
UniProt:	P35968
Pathways:	RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling

Application Details

Application Notes:	Optimal working dilution should be determined by the investigator.
Restrictions:	For Research Use only

Handling

Format:	Lyophilized
Reconstitution:	Centrifuge vial prior to opening. Reconstitute with sterile water to a concentration of 0.1-1.0 mg/mL.
Concentration:	Lot specific
Buffer:	Lyophilized.
Storage:	4 °C,-20 °C
Storage Comment:	Short Term Storage: +4°C

Handling

	Long Term Storage: -20°C Stable for at least 6 months after receipt when stored at -20°C.
Expiry Date:	6 months

Images



Flow Cytometry

Image 1. FACS analysis of VEGFR-2/KDR expression in HUVECs (left) and EPCs derived from PBMcs (right) using anti-VEGFR-2 (human), mAb (EIC) at 5µg/ml and a PE goat anti-mouse IgG at 5µg/ml.